Zanubrutinib: past, present, and future

[1]  P. Ganly,et al.  Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: Updated analysis of the ROSEWOOD study. , 2023, Journal of Clinical Oncology.

[2]  A. Frustaci,et al.  Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities , 2023, Cancers.

[3]  P. Ganly,et al.  Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study , 2022, Blood.

[4]  C. Buske,et al.  Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia , 2022, American journal of hematology.

[5]  I. Flinn,et al.  NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton's Tyrosine Kinase-Targeted Protein Degrader, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies , 2022, Blood.

[6]  P. Zinzani,et al.  Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial , 2022, Blood.

[7]  Abstracts from the 2022 Lymphoma, Leukemia and Myeloma Congress October 18-22, 2022. , 2022, American journal of hematology/oncology.

[8]  E. Thompson,et al.  Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance , 2022, Blood advances.

[9]  E. Steliarova-Foucher,et al.  Global patterns of non‐Hodgkin lymphoma in 2020 , 2022, International journal of cancer.

[10]  M. Dwyer,et al.  NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022. , 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

[11]  Michael L. Wang,et al.  BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma—Finding a Dancing Partner , 2022, Current Oncology Reports.

[12]  Dengju Li,et al.  A two‐part, single‐arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed/refractory B‐cell malignancies , 2022, British journal of haematology.

[13]  C. Dearden,et al.  Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia , 2022, Blood advances.

[14]  W. Novotny,et al.  Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study , 2022, Blood.

[15]  P. Jain,et al.  Zanubrutinib in lymphoproliferative disorders: a comprehensive review , 2022, Therapeutic advances in hematology.

[16]  J. Byrd,et al.  Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice , 2021, Frontiers in Oncology.

[17]  R. Advani,et al.  NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

[18]  M. Dimopoulos,et al.  Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies , 2021, Blood advances.

[19]  Michael L. Wang,et al.  Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials , 2021, Journal of Hematology & Oncology.

[20]  S. Opat,et al.  Clinical pharmacology and PK/PD translation of the second-generation Bruton’s tyrosine kinase inhibitor, zanubrutinib , 2021, Expert review of clinical pharmacology.

[21]  W. Novotny,et al.  Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma , 2021, Leukemia & lymphoma.

[22]  Michael L. Wang,et al.  Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. , 2021, Blood advances.

[23]  C. I. Smith,et al.  Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects , 2021, Frontiers in Cell and Developmental Biology.

[24]  Prashanth Rawla,et al.  Epidemiology of Non-Hodgkin’s Lymphoma , 2021, Medical sciences.

[25]  W. Novotny,et al.  Evaluation of drug interaction potential of zanubrutinib with cocktail probes representative of CYP3A4, CYP2C9, CYP2C19, P‐gp and BCRP , 2020, British journal of clinical pharmacology.

[26]  Dahlia R. Weiss,et al.  Nx-2127, a Degrader of BTK and IMiD Neosubstrates, for the Treatment of B-Cell Malignancies , 2020 .

[27]  I. Flinn,et al.  Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma. , 2020, Blood advances.

[28]  W. Novotny,et al.  Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: three years of follow-up. , 2020, Blood.

[29]  L. Sellner,et al.  Ibrutinib for improved chimeric antigen receptor T‐cell production for chronic lymphocytic leukemia patients , 2020, International journal of cancer.

[30]  S. Molica,et al.  The Evolution of Targeted Therapies in Chronic Lymphocytic Leukaemia , 2020, Current Hematologic Malignancy Reports.

[31]  R. Gale,et al.  Chronic lymphocytic leukemia in 2020: a surfeit of riches? , 2020, Leukemia.

[32]  W. Novotny,et al.  Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study , 2020, Journal of Hematology & Oncology.

[33]  R. Elstrom,et al.  Phase 1 study of selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. , 2019, Blood.

[34]  L. Staudt,et al.  Pathogenic B‐cell receptor signaling in lymphoid malignancies: New insights to improve treatment , 2019, Immunological reviews.

[35]  Zhiwei Wang,et al.  Discovery of Zanubrutinib (BGB-3111), a Novel, Potent and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase. , 2019, Journal of medicinal chemistry.

[36]  R. Elstrom,et al.  UPDATED SAFETY AND EFFICACY DATA IN THE PHASE 1 TRIAL OF PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) TREATED WITH BRUTON TYROSINE KINASE (BTK) INHIBITOR ZANUBRUTINIB (BGB‐3111) , 2019, Hematological Oncology.

[37]  S. O'brien,et al.  Evolution of CLL treatment — from chemoimmunotherapy to targeted and individualized therapy , 2018, Nature Reviews Clinical Oncology.

[38]  O. McCarty,et al.  Ibrutinib‐associated bleeding: pathogenesis, management and risk reduction strategies , 2017, Journal of thrombosis and haemostasis : JTH.

[39]  C. Flowers,et al.  Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. , 2017, Blood.

[40]  W. Wilson,et al.  Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma. , 2016, Blood.

[41]  J. Byrd,et al.  Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. , 2016, Blood.

[42]  J. Byrd,et al.  Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. , 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

[43]  J. Byrd,et al.  Non-Hodgkin's lymphomas, version 4.2014. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

[44]  S. Treon,et al.  Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. , 2014, Blood.

[45]  A. Michael,et al.  The Promising Impact of Ibrutinib, a Bruton's Tyrosine Kinase Inhibitor, for the Management of Lymphoid Malignancies , 2014, Pharmacotherapy.

[46]  E. Davis,et al.  Targeting B-cell receptor signaling: changing the paradigm. , 2013, Hematology. American Society of Hematology. Education Program.

[47]  S. Alkan,et al.  Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis. , 2013, Leukemia research.

[48]  A. Adjei,et al.  Understanding, recognizing, and managing toxicities of targeted anticancer therapies , 2013, CA: a cancer journal for clinicians.

[49]  J. Byrd,et al.  The B-cell receptor signaling pathway as a therapeutic target in CLL. , 2012, Blood.

[50]  H. Brenner,et al.  Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century. , 2008, Blood.

[51]  F. Uckun,et al.  Brutons Tyrosine Kinase as a New Therapeutic Target , 2007 .

[52]  L. Honigberg,et al.  Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase , 2007, ChemMedChem.

[53]  Ornella Parolini,et al.  Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia , 1993, Cell.

[54]  D. Bentley,et al.  The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases , 1993, Nature.

[55]  O. C. Bruton.  Agammaglobulinemia. , 1952, Pediatrics.

[56]  V. Kaur,et al.  Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib , 2017, Annals of Hematology.

[57]  J. Byrd,et al.  NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

[58]  Xavier Woot de Trixhe,et al.  Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies , 2014, Cancer Chemotherapy and Pharmacology.